Lafaye Pierre, Li Tengfei
Institut Pasteur, Plate forme d'Ingénierie des Anticorps, C2RT, Paris, France.
Université Paris Diderot, Paris 7, France.
Comp Immunol Microbiol Infect Dis. 2018 Oct;60:17-22. doi: 10.1016/j.cimid.2018.09.009. Epub 2018 Sep 25.
Camelids produce both conventional heterotetrameric antibodies and homodimeric heavy-chain only antibodies. The antigen-binding region of such homodimeric heavy-chain only antibodies consists of one single domain, called VHH. VHHs provide many advantages over conventional full-sized antibodies and currently used antibody-based fragments (Fab, scFv), including high specificity, stability and solubility, and small size, allowing them to recognize unusual antigenic sites and deeply penetrate tissues. Since their discovery, VHHs have been used extensively in diagnostics and therapy. In recent decades, the number of outbreaks of diseases transmissible from animals to humans has been on the rise. In this review, we evaluate the status of VHHs as diagnostic and therapeutic biomolecular agents for the detection and treatment of zoonotic diseases, such as bacterial, parasitic, and viral zoonosis. VHHs show great adaptability to inhibit or neutralize pathogenic agents for the creation of multifunctional VHH-based diagnostic and therapeutic molecules against zoonotic diseases.
骆驼科动物既能产生传统的异源四聚体抗体,也能产生仅由重链组成的同型二聚体抗体。这种仅由重链组成的同型二聚体抗体的抗原结合区域由一个单一结构域组成,称为VHH。与传统的全尺寸抗体和目前使用的基于抗体的片段(Fab、scFv)相比,VHH具有许多优势,包括高特异性、稳定性和溶解性,以及小尺寸,使其能够识别不寻常的抗原位点并深入穿透组织。自发现以来,VHH已广泛应用于诊断和治疗。近几十年来,动物源性疾病的暴发数量一直在上升。在这篇综述中,我们评估了VHH作为诊断和治疗生物分子试剂在检测和治疗人畜共患病(如细菌性、寄生虫性和病毒性人畜共患病)方面的现状。VHH在抑制或中和病原体方面表现出很强的适应性,可用于创建针对人畜共患病的多功能基于VHH的诊断和治疗分子。